IRVINE, Calif. — May 13, 2024 — Immunis, Inc., a private biotech developing novel secretome therapeutics for age-related diseases and immune dysfunction, is thrilled to announce that Chairman Dr. Hans Keirstead was invited as a speaker at the Wallace McCain Institute (WMI) in Canada. Founded in 2006 in New Brunswick, the organization aims to support entrepreneurial leaders in transforming the economic landscape of the Greater Atlantic Area. The institute is comprised of over 572 business leaders and over 13K employees, with its CEO members generating over $1.86 billion in annual revenue. From their Entrepreneurial Leaders Program to their Strategic Executives Program and ECHO (peer program for the children of entrepreneurs in multi-generational family businesses), WMI surrounds entrepreneurs with opportunities to become superior businesspeople who run better businesses.

With Dr. Keirstead’s decades of experience and success within the biotech industry, he is a true model of entrepreneurial success. Each of Dr. Keirstead’s three prior biotechnology firms was acquired by major pharmaceutical companies for 2.5X-9.5X returns to investors, after return of investment capital. He also currently holds board positions in several leading biotech companies including Immunis Inc., AIVITA Biomedical, and the global Human Immune Project. Before his transition into biotech, Dr. Keirstead had an incredibly fruitful 15-year tenure as a Professor of Anatomy and Neurobiology at the University of California Irvine.

We are confident that his WMI fireside chat will motivate others to maximize their potential and become the best version of themselves within their respective industries. Dr. Keirstead will join the list of 35 high-profile speakers who have spoken at this exclusive event including Frank McKenna, Blaine Higgs, David McKay, Senator Stan Kutcher, Annette Verschuren,  bestselling authors and recipients of the Order of Canada. We are delighted to celebrate this honor and the many achievements of Dr. Keirstead that have afforded him this incredible platform in which he can share his entrepreneurial journey.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com